BDTX · NASDAQ
Black Diamond Therapeutics, Inc.
$1.80 +0.05 (+2.86%)
Company overview
Black Diamond Therapeutics, Inc., a biotechnology company, discovers, develops, and commercializes medicines for patients with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to target oncogenic proteins defined by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations, and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II, and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $103M
- Employees
- 24
- Headquarters
- Cambridge, MA
- Website
- blackdiamondtherapeutics.com
- CEO
- Mark A. Velleca
- Listed
- January 31, 2020
- P/E
- -2.37
- Dividend yield
- 0.00%
Company financials
- Revenue
- $0.00
- Gross profit
- -$113,000
- Operating income
- -$53.3M
- EBITDA
- -$40.3M
- Net income
- -$43.2M
- EPS
- -$0.76
- Total assets
- $133M
- Total debt
- $17.9M
- Earnings yield
- -42.22%
No geographic segmentation.
Showing FY 2025
BDTX
1D
NASDAQ
O1.79H1.86L1.75C1.75-0.03 (-1.69%)Vol494.37K
News